Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BVS
Upturn stock ratingUpturn stock rating

Bioventus Inc (BVS)

Upturn stock ratingUpturn stock rating
$7.25
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: BVS (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $12.75

1 Year Target Price $12.75

Analysts Price Target For last 52 week
$12.75 Target price
52w Low $5.81
Current$7.25
52w High $14.38

Analysis of Past Performance

Type Stock
Historic Profit 79.35%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 484.97M USD
Price to earnings Ratio 241.67
1Y Target Price 12.75
Price to earnings Ratio 241.67
1Y Target Price 12.75
Volume (30-day avg) 3
Beta 0.83
52 Weeks Range 5.81 - 14.38
Updated Date 08/29/2025
52 Weeks Range 5.81 - 14.38
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.03

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate 0.21
Actual 0.21

Profitability

Profit Margin 0.33%
Operating Margin (TTM) 12.45%

Management Effectiveness

Return on Assets (TTM) 3.64%
Return on Equity (TTM) 1.39%

Valuation

Trailing PE 241.67
Forward PE 11.32
Enterprise Value 793297196
Price to Sales(TTM) 0.86
Enterprise Value 793297196
Price to Sales(TTM) 0.86
Enterprise Value to Revenue 1.41
Enterprise Value to EBITDA 9.13
Shares Outstanding 66892300
Shares Floating 33720410
Shares Outstanding 66892300
Shares Floating 33720410
Percent Insiders 11.77
Percent Institutions 73.49

ai summary icon Upturn AI SWOT

Bioventus Inc

stock logo

Company Overview

overview logo History and Background

Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew. It focuses on developing and marketing orthobiologic solutions to treat musculoskeletal conditions. The company has grown through organic expansion and acquisitions.

business area logo Core Business Areas

  • Active Healing Therapies: This segment focuses on products that promote bone and tissue healing through electrical stimulation and ultrasound technologies.
  • Surgical Solutions: This segment provides bone graft substitutes and other solutions used in surgical procedures to aid in bone regeneration and fracture repair.
  • Pain Treatments: This segment focuses on non-surgical pain relief solutions using viscosupplementation and bracing.

leadership logo Leadership and Structure

The CEO is Tony Bihl. The company operates with a functional organizational structure, dividing responsibilities across departments such as R&D, marketing, sales, and operations.

Top Products and Market Share

overview logo Key Offerings

  • DUROLANE: DUROLANE is a single-injection hyaluronic acid (HA) product used to treat osteoarthritis knee pain. Competitors include SYNVISC, ORTHOVISC and GEL-ONE. Data on market share is difficult to get a precise number, but Durolane is one of the key products in the OA knee market. Revenue associated with this product are substantial, comprising a significant portion of the company's pain treatment revenue.
  • EXOGEN: EXOGEN is an ultrasound bone healing system used to treat non-union fractures and accelerate fracture healing. Competitors include OrthoFIX, Smith & Nephew and Zimmer Biomet. Exogen is a well known bone healing system within the space with substantial share but specific data is difficult to get precise values.
  • OSTEOAMP: OSTEOAMP is a family of bone graft substitutes used in spinal fusion and other orthopedic procedures. Competitors include Medtronic, Stryker, and DePuy Synthes (Johnson & Johnson). The exact market share information or specific revenue of this product is unavailable

Market Dynamics

industry overview logo Industry Overview

The orthobiologics market is experiencing growth due to an aging population, increasing incidence of musculoskeletal disorders, and technological advancements. The market is competitive, with several large players and smaller innovative companies.

Positioning

Bioventus Inc. is positioned as a key player in the orthobiologics market, focusing on non-surgical and surgical solutions for bone and joint health. It leverages its proprietary technologies and established distribution network to maintain a competitive edge.

Total Addressable Market (TAM)

The global orthobiologics market is projected to reach over $11 billion by 2028. Bioventus is well-positioned to capture a portion of this expanding market through its diverse product portfolio and innovation.

Upturn SWOT Analysis

Strengths

  • Diverse product portfolio
  • Established distribution network
  • Proprietary technologies
  • Strong brand recognition in some product categories

Weaknesses

  • Relatively smaller size compared to larger competitors
  • Reliance on key products
  • Historically inconsistent profitability
  • High debt levels

Opportunities

  • Expanding into new geographic markets
  • Developing new products and indications
  • Acquiring complementary technologies or businesses
  • Increasing adoption of orthobiologics

Threats

  • Intense competition
  • Pricing pressures
  • Regulatory changes
  • Reimbursement challenges
  • Product liability claims

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • JNJ
  • ZBH

Competitive Landscape

Bioventus faces stiff competition from larger, more established players. Its competitive advantages include its focus on orthobiologics and its proprietary technologies. Disadvantages include its smaller size and reliance on key products.

Major Acquisitions

Misonix, Inc.

  • Year: 2021
  • Acquisition Price (USD millions): 518
  • Strategic Rationale: Expanded Bioventus' surgical solutions portfolio with ultrasonic medical devices used for wound debridement and bone grafting.

Growth Trajectory and Initiatives

Historical Growth: Bioventus has grown historically through product innovation, strategic acquisitions, and geographic expansion.

Future Projections: Analyst projections suggest continued growth driven by demand for orthobiologics and new product launches. Specific projections for financial figures are unavailable.

Recent Initiatives: Recent initiatives include focusing on cost management, product portfolio optimization, and expansion into international markets.

Summary

Bioventus is a key player in the orthobiologics market with a diverse product portfolio but faces strong competition. Its strength lies in proprietary technologies and established distribution. Areas to watch include managing debt and navigating reimbursement challenges. Continued innovation and market expansion will be crucial for sustained growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • Industry reports
  • Analyst estimates

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bioventus Inc

Exchange NASDAQ
Headquaters Durham, NC, United States
IPO Launch date 2021-02-11
President, CEO & Director Mr. Robert E. Claypoole
Sector Healthcare
Industry Medical Devices
Full time employees 950
Full time employees 950

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.